All In Biotech

Drug Trial Radar · NCT01098487

A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Last checked: Nov 20, 2026Latest source record: Mar 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

167

Actual

Start

May 2010

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term effect of eltrombopag on bone marrow fibers. The study will also describe the long-term safety and tolerability of oral eltrombopag treatment in subjects with chronic ITP.

Conditions

  • Purpura, Thrombocytopaenic, Idiopathic

Interventions

  • Eltrombopag olamineDrug

    Thrombopoietin receptor agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at BaselineTime frame: Baseline
  2. Number of Participants With a Positive or Negative Collagen Level at BaselineTime frame: Baseline
  3. Number of Participants With Indicated Grade Change From Baseline in the EC Grading Scale at 1 YearTime frame: Baseline and 1 year
  4. Number of Participants With Indicated Change From Baseline in the EC Grading Scale at 2 YearsTime frame: Baseline and 2 years
  5. Number of Participants With a Positive or Negative Collagen Level at 1 YearTime frame: 1 year
  6. Number of Participants With a Positive or Negative Collagen Level at 2 YearTime frame: 2 years

Locations

34 sites in 11 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Hradec Králové, Czechia

  • GSK Investigational Site

    Olomouc, Czechia

  • GSK Investigational Site

    Prague, Czechia

  • GSK Investigational Site

    Caen, France

  • GSK Investigational Site

    Créteil, France

  • GSK Investigational Site

    Pessac, France

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Munich, Bavaria, Germany

  • GSK Investigational Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Düsseldorf, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Essen, North Rhine-Westphalia, Germany

  • GSK Investigational Site

    Berlin, State of Berlin, Germany

  • GSK Investigational Site

    Shatin, New Territories, Hong Kong

  • GSK Investigational Site

    Debrecen, Hungary

  • GSK Investigational Site

    Győr, Hungary

  • GSK Investigational Site

    Szeged, Hungary

  • GSK Investigational Site

    Ludhiana, India

  • GSK Investigational Site

    Pune, India

  • GSK Investigational Site

    Surat, India

  • GSK Investigational Site

    Vellore, India

  • GSK Investigational Site

    Bologna, Emilia-Romagna, Italy

  • GSK Investigational Site

    Milan, Lombardy, Italy

  • GSK Investigational Site

    Milan, Lombardy, Italy

  • GSK Investigational Site

    Padova, Veneto, Italy

  • GSK Investigational Site

    Vicenza, Veneto, Italy

  • GSK Investigational Site

    Karachi, Pakistan

  • GSK Investigational Site

    Lahore, Pakistan

  • GSK Investigational Site

    Moscow, Russia

  • GSK Investigational Site

    Novosibirsk, Russia

  • GSK Investigational Site

    Saint Petersburg, Russia

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, South Korea

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.